« Back
Home /
PROTAC ERα Degrader-1

PROTAC ERα Degrader-1

Item no.	HY-112098-1mg
Manufacturer	MedChem Express
CASRN	2417369-94-7
Amount	1 mg
Quantity options	1 mg 25 mg 50 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Purity	96.68
Citations	[1]Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
Smiles	OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)NC)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(C8=CC=CC=C8)\CC)C=C1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Estrogen Receptor/ERR; PROTACs
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, stored under nitrogen)
Molecular Weight	1120.29
Product Description	PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 200 mg/mL (ultrasonic)
Manufacturer - Pathway	PROTAC; Vitamin D Related/Nuclear Receptor
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question